REALITI-C: Real world effectiveness of mepolizumab in treating chronic obstructive pulmonary disease (COPD)

Participant is >=40 years of age at enrollment

• Participant has had a documented diagnosis of COPD for at least 12 months, as per physician’s judgment
• Confirmed availability of medical records for at least 12 months prior to inclusion in the study
• Participant has newly initiated treatment with add-on mepolizumab for COPD with an eosinophilic phenotype or characterized by raised blood eosinophils (as per the country-specific label for COPD). Physician’s decision to treat the participant with add-on mepolizumab was made independently of the participants participation in this study (as per Standard of Care)
• Participant has been on maintenance inhaled therapy for a minimum of 3 months prior to enrollment
• Participant is willing and able to complete study-related questionnaires
• Participant provides voluntary signed informed consent to participate in the study before inclusion in the study

Participant has received mepolizumab for treating COPD more than 7 days prior to the enrollment

• Participant has received mepolizumab for indications other than COPD anytime within 12 months prior to the enrollment.
• Participant has a documented history of failure with anti- Interleukin (IL)-5/5 receptor (r) therapy, per physician judgment, for any indication
• Participant has any condition that—in the opinion of the investigator—may interfere with the participants ability to participate in the study (such as short life expectancy, substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the participant from completing visits and assessments
• Participant currently participates in any interventional clinical trial